Search Results - Deborah K. Armstrong

Refine Results
  1. 1
    Relapsed Ovarian Cancer: Challenges and Management Strategies for a Chronic Disease

    Relapsed Ovarian Cancer: Challenges and Management Strategies for a Chronic Disease by Deborah K. Armstrong

    Published 2002
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  2. 2
    New Therapies for Ovarian Cancer

    New Therapies for Ovarian Cancer by Deborah K. Armstrong

    Published 2018
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  3. 3
    Recent progress in the diagnosis and treatment of ovarian cancer

    Recent progress in the diagnosis and treatment of ovarian cancer by Danijela Jelovac, Deborah K. Armstrong

    Published 2011
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  4. 4
    Is the Easier Way Ever the Better Way?

    Is the Easier Way Ever the Better Way? by S. Dennis, Robert E. Bristow, Deborah K. Armstrong, Beth Y. Karlan

    Published 2011
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  5. 5
    Interleukin-3 and bryostatin-1 mediate hyperphosphorylation of BCL2 alpha in association with suppression of apoptosis.

    Interleukin-3 and bryostatin-1 mediate hyperphosphorylation of BCL2 alpha in association with suppression of apoptosis. by W. Stratford May, P G Tyler, Takahiko Ito, Deborah K. Armstrong, K A Qatsha, N E Davidson

    Published 1994
    Get full text
    Artigo
    Save to List
    Saved in:
  6. 6
    Weight Change in Breast Cancer Survivors Compared to Cancer-Free Women: A Prospective Study in Women at Familial Risk of Breast Cancer

    Weight Change in Breast Cancer Survivors Compared to Cancer-Free Women: A Prospective Study in Women at Familial Risk of Breast Cancer by Amy L. Gross, Betty J. May, Jennifer E. Axilbund, Deborah K. Armstrong, Richard B.S. Roden, Kala Visvanathan

    Published 2015
    Get full text
    Artigo
    Save to List
    Saved in:
  7. 7
    Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: A Gynecologic Oncology Group study

    Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: A Gynecologic Oncology Group study by Lisa M. Landrum, James Java, Cara Mathews, Grainger S. Lanneau, Larry J. Copeland, Deborah K. Armstrong, Joan L. Walker

    Published 2013
    Get full text
    Artigo
    Save to List
    Saved in:
  8. 8
    Survival in Women With Grade 1 Serous Ovarian Carcinoma

    Survival in Women With Grade 1 Serous Ovarian Carcinoma by Amanda N. Fader, James Java, Stefanie Ueda, Robert E. Bristow, Deborah K. Armstrong, Michael A. Bookman, David M. Gershenson

    Published 2013
    Get full text
    Artigo
    Save to List
    Saved in:
  9. 9
    Long-Term Survival Advantage and Prognostic Factors Associated With Intraperitoneal Chemotherapy Treatment in Advanced Ovarian Cancer: A Gynecologic Oncology Group Study

    Long-Term Survival Advantage and Prognostic Factors Associated With Intraperitoneal Chemotherapy Treatment in Advanced Ovarian Cancer: A Gynecologic Oncology Group Study by Devansu Tewari, James Java, Ritu Salani, Deborah K. Armstrong, Maurie Markman, Thomas J. Herzog, Bradley J. Monk, John K. Chan

    Published 2015
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  10. 10
    Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: A Gynecologic Oncology Group study

    Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: A Gynecologic Oncology Grou... by Angeles Alvarez Secord, John A. Blessing, Deborah K. Armstrong, William H. Rodgers, Zoe Miner, Mack N. Barnes, George Lewandowski, Robert S. Mannel

    Published 2008
    Get full text
    Artigo
    Save to List
    Saved in:
  11. 11
    Centralization of care for patients with advanced‐stage ovarian cancer

    Centralization of care for patients with advanced‐stage ovarian cancer by Robert E. Bristow, Antonio Santillan, Teresa Diaz‐Montes, Ginger J. Gardner, Robert Giuntoli, Benjamin C. Meisner, Kevin D. Frick, Deborah K. Armstrong

    Published 2007
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  12. 12
    Comparison of Paclitaxel-, 5-Fluoro-2′-deoxyuridine-, and Epidermal Growth Factor (EGF)-induced Apoptosis

    Comparison of Paclitaxel-, 5-Fluoro-2′-deoxyuridine-, and Epidermal Growth Factor (EGF)-induced Apoptosis by Timothy Kottke, April L. Blajeski, L. Miguel Martins, Peter W. Mesner, Nancy E. Davidson, William C. Earnshaw, Deborah K. Armstrong, Scott H. Kaufmann

    Published 1999
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  13. 13
    Relationship Between<i>ERCC1</i>Polymorphisms, Disease Progression, and Survival in the Gynecologic Oncology Group Phase III Trial of Intraperitoneal Versus Intravenous Cisplatin and Paclitaxel for Stage III Epithelial Ovarian Cancer

    Relationship Between<i>ERCC1</i>Polymorphisms, Disease Progression, and Survival in the Gynecologic Oncology Group Phase III Trial of Intraperitoneal Versus Intravenous Cisplatin a... by Thomas C. Krivak, Kathleen M. Darcy, Chunqiao Tian, Deborah K. Armstrong, Bora Baysal, Holly H. Gallion, Christine B. Ambrosone, Julie A. DeLoia

    Published 2008
    Get full text
    Artigo
    Save to List
    Saved in:
  14. 14
    Evaluation of osteopenia and osteoporosis in younger breast cancer survivors compared with cancer-free women: a prospective cohort study

    Evaluation of osteopenia and osteoporosis in younger breast cancer survivors compared with cancer-free women: a prospective cohort study by Cody Ramin, Betty J. May, Richard B.S. Roden, Mikiaila M. Orellana, Brenna Hogan, Michelle S. McCullough, Dana Petry, Deborah K. Armstrong, Kala Visvanathan

    Published 2018
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  15. 15
    A Comparison of Quality-of-Life Domains and Clinical Factors in Ovarian Cancer Patients: A Gynecologic Oncology Group Study

    A Comparison of Quality-of-Life Domains and Clinical Factors in Ovarian Cancer Patients: A Gynecologic Oncology Group Study by Vivian E. von Gruenigen, Helen Q. Huang, Karen M. Gil, Heidi Gibbons, Bradley J. Monk, Peter G. Rose, Deborah K. Armstrong, David Cella, Lari Wenzel

    Published 2010
    Get full text
    Artigo
    Save to List
    Saved in:
  16. 16
    Assessment of factors that contribute to decreased quality of life in Gynecologic Oncology Group ovarian cancer trials

    Assessment of factors that contribute to decreased quality of life in Gynecologic Oncology Group ovarian cancer trials by Vivian E. von Gruenigen, Helen Q. Huang, Karen M. Gil, Heidi Gibbons, Bradley J. Monk, Peter G. Rose, Deborah K. Armstrong, David Cella, Lari Wenzel

    Published 2009
    Get full text
    Artigo
    Save to List
    Saved in:
  17. 17
    BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study

    BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study by Jamie Lesnock, Kathleen M. Darcy, Chunqiao Tian, Julie A. DeLoia, Melissa M. Thrall, Chris Zahn, Deborah K. Armstrong, Michael J. Birrer, Thomas C. Krivak

    Published 2013
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  18. 18
    Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer

    Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer by Deborah K. Armstrong, Brian N. Bundy, Lari Wenzel, Helen Q. Huang, Rebecca N. Baergen, Shashikant Lele, Larry J. Copeland, Joan L. Walker, Robert A. Burger

    Published 2006
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  19. 19
    CA‐125 change after chemotherapy in prediction of treatment outcome among advanced mucinous and clear cell epithelial ovarian cancers

    CA‐125 change after chemotherapy in prediction of treatment outcome among advanced mucinous and clear cell epithelial ovarian cancers by Chunqiao Tian, Maurie Markman, Richard J. Zaino, Robert F. Ozols, William P. McGuire, Franco M. Muggia, Peter G. Rose, David R. Spriggs, Deborah K. Armstrong

    Published 2009
    Get full text
    Revisão
    Save to List
    Saved in:
  20. 20
    The prognostic significance of pre- and post-treatment CA-125 in grade 1 serous ovarian carcinoma: A Gynecologic Oncology Group study

    The prognostic significance of pre- and post-treatment CA-125 in grade 1 serous ovarian carcinoma: A Gynecologic Oncology Group study by Amanda N. Fader, James Java, Thomas C. Krivak, Robert E. Bristow, Ana I. Tergas, Michael A. Bookman, Deborah K. Armstrong, Edward J. Tanner, David M. Gershenson

    Published 2013
    Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: